Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Drugs for NASH and HIV Infection: Great Expectations for a Great Need
Giovanni Guaraldi, James Maurice, Catia Marzolini, et al.
Hepatology (2020) Vol. 71, Iss. 5, pp. 1831-1844
Closed Access | Times Cited: 22

Showing 22 citing articles:

New Drugs for Hepatic Fibrosis
Liang Shan, Fengling Wang, Dandan Zhai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 44
Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner
Xiaojing Wang, Liangjing Wang, Lin Geng, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5843-5843
Open Access | Times Cited: 27
The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV
Giovanni Guaraldi, Jovana Milić, Stefano Renzetti, et al.
AIDS (2024) Vol. 38, Iss. 9, pp. 1323-1332
Open Access | Times Cited: 7
Anti-fibrotic treatments for chronic liver diseases: The present and the future
Naoshi Odagiri, Tsutomu Matsubara, Misako Sato, et al.
Clinical and Molecular Hepatology (2020) Vol. 27, Iss. 3, pp. 413-424
Open Access | Times Cited: 34
NASH in HIV
Adriana Cervo, Mohamed Shengir, Keyur Patel, et al.
Current HIV/AIDS Reports (2020) Vol. 17, Iss. 6, pp. 601-614
Closed Access | Times Cited: 32
Infections at the nexus of metabolic-associated fatty liver disease
Joost Boeckmans, Matthias Rombaut, Thomas Demuyser, et al.
Archives of Toxicology (2021) Vol. 95, Iss. 7, pp. 2235-2253
Open Access | Times Cited: 25
Nutritional and Lifestyle Therapy for NAFLD in People with HIV
Felice Cinque, Annalisa Cespiati, Rosa Lombardi, et al.
Nutrients (2023) Vol. 15, Iss. 8, pp. 1990-1990
Open Access | Times Cited: 10
Metabolic Dysfunction-Associated Steatotic Liver Disease in People Living with HIV—Limitations on Antiretroviral Therapy Selection
Georgios Kalopitas, Konstantinos Arvanitakis, Οlga Tsachouridou, et al.
Life (2024) Vol. 14, Iss. 6, pp. 742-742
Open Access | Times Cited: 3
Steatotic liver disease and HIV: an agenda for 2030
Juan M. Pericàs, Anish Arora, Carlotta Riebensahm, et al.
The Lancet HIV (2024) Vol. 11, Iss. 8, pp. e561-e566
Closed Access | Times Cited: 3
Fibroscan–Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus
Giada Sebastiani, Jovana Milić, Dana Kablawi, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 3, pp. 396-404
Closed Access | Times Cited: 7
Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections
Sandra Franco, Daniela Buccione, Cristina Tural, et al.
AIDS (2021) Vol. 35, Iss. 9, pp. 1355-1363
Closed Access | Times Cited: 14
Letter to the Editor: People living with HIV and NAFLD—A population left behind in the global effort for liver fibrosis screening?
Giada Sebastiani, Jovana Milić, Emmanuel Tsochatzis, et al.
Hepatology (2023) Vol. 78, Iss. 5, pp. E87-E88
Open Access | Times Cited: 4
Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort
Felice Cinque, Sahar Saeed, Dana Kablawi, et al.
BMJ Open (2023) Vol. 13, Iss. 8, pp. e076547-e076547
Open Access | Times Cited: 3
Optimizing Cardiometabolic Risk in People Living with Human Immunodeficiency Virus: A Deep Dive into an Important Risk Enhancer
Elizabeth A Kobe, Aarti Thakkar, Sarina Matai, et al.
American Journal of Preventive Cardiology (2024) Vol. 20, pp. 100888-100888
Open Access
Primary Care Screening for Nonalcoholic Fatty Liver Disease Among People With HIV in the United States: A Real-World Provider Survey
Jennifer C. Price, Kyoko Hirose, Naga Chalasani, et al.
Journal of the Association of Nurses in AIDS Care (2024)
Closed Access
Switch to a raltegravir‐based antiretroviral regimen in people with HIV and non‐alcoholic fatty liver disease: A randomized controlled trial
Mohamed Shengir, Bertrand Lebouché, Wesal Elgretli, et al.
HIV Medicine (2023) Vol. 25, Iss. 1, pp. 135-142
Open Access | Times Cited: 1
Are Separate Clinical Trials Still Required in Nonalcoholic Steatohepatitis for Patients With and Without Human Immunodeficiency Virus (HIV)?
James Maurice, Maud Lemoine
Clinical Infectious Diseases (2020) Vol. 72, Iss. 5, pp. 908-909
Closed Access | Times Cited: 1
Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients
Giada Sebastiani, Jovana Milić, Adriana Cervo, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 2, pp. 282-282
Open Access | Times Cited: 1
HIV: hepatic manifestations of HIV and antiretroviral therapy
Yvonne Ayerki Nartey, Kali Zhou, Min Kim, et al.
Elsevier eBooks (2023), pp. 525-555
Closed Access
Reply to Maurice and Lemoine
Lindsay T. Fourman, Takara L. Stanley, Steven Grinspoon
Clinical Infectious Diseases (2020) Vol. 72, Iss. 5, pp. 909-909
Open Access
Drugs to Modify Liver Fibrosis Progression and Regression
Marina Vilaseca, Jordi Gracia‐Sancho
Springer eBooks (2022), pp. 201-218
Closed Access
Anti-fibrotic Therapy for Chronic Liver Diseases Review
Maged Naser, Mohamed M. Naser, Lamia H. Shehata
International Journal of Progressive Sciences and Technologies (2021) Vol. 29, Iss. 2, pp. 88-102
Closed Access
Page 1

Scroll to top